{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:02:17Z","timestamp":1768291337881,"version":"3.49.0"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"Research Fund of Istanbul University, Istanbul, Turkey","award":["Project No: 46492"],"award-info":[{"award-number":["Project No: 46492"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nPurpose To investigate the relationship of Fibroblast Growth Factor Receptor-4 (FGFR-4) expression with radiologic, pathologic, and clinical parameters in pituitary adenomas.<\/jats:p><jats:p>\nMethods Among 307 patients who underwent pituitary surgery for a pituitary adenoma between 2000 and 2015, we included 161 patients (53 gonadotroph, 26 corticotroph, 25 null cell, 22 lactotroph, 13 somatotroph, 8 adenomas with unusual combination, 7 Pit-1 positive adenomas, and 7 lactosomatotroph) based on availability of pathology specimens. Patients\u2019 radiologic, pathologic, and clinical parameters were determined. FGFR-4 immunostaining was evaluated using a semi-quantitative histologic score (H-score).<\/jats:p><jats:p>\nResults The mean follow-up period was 61 (IQR=32\u201384) months. The median H-scores for FGFR-4 were higher in patients without remission, those with residual lesion, and T2-hyperintense adenoma (p&lt;0.05). Ki-67 level was higher in patients without remission compared to those in remission (p&lt;0.05). The mean Ki-67 levels did not differ between patients with and without residual lesion or T2-hyperintense tumor (p&gt;0.05). There was no significant difference (p&gt;0.05) when the H-score and Ki-67 levels were assessed in terms of sex, sellar-dural invasion, Knosp and a grading system for superior, inferior, parasellar, anterior and posterior tumor extension Classification, tumor function or presence of poor subtype. Adenomas with Ki-67 expression \u22653% had higher FGFR4 expression levels than those with &lt;3% expression (p=0.002). There was a weak positive correlation between H-score and Ki-67 (p=0.011; r=0.201).<\/jats:p><jats:p>\nConclusions Higher levels of FGFR-4 in pituitary adenomas could be use a marker for more aggressive tumor behavior.<\/jats:p>","DOI":"10.1055\/a-1523-7216","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:59:56Z","timestamp":1626184796000},"page":"125-133","source":"Crossref","is-referenced-by-count":4,"title":["Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features"],"prefix":"10.1055","volume":"130","author":[{"given":"Emre","family":"Durcan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Ela","family":"Keskin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, T.C. Demiroglu Bilim University, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande Mefkure","family":"Ozkaya","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabri","family":"Sirolu","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnostic, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Sahin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozge Polat","family":"Korkmaz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurperi","family":"Gazioglu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, T.C. Demiroglu Bilim University, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Necmettin","family":"Tanriover","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nil","family":"Comunoglu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buge","family":"Oz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Kizilkilic","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnostic, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-140X","authenticated-orcid":false,"given":"Pinar","family":"Kadioglu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1530\/JME-12-0113","article-title":"Biomarkers of aggressive pituitary adenomas","volume":"49","author":"O Mete","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"043","DOI":"10.1385\/ENDO:28:1:043","article-title":"Genetics and proteomics of pituitary tumors","volume":"28","author":"S L Asa","year":"2005","journal-title":"Endocrine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case\u2013control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"J Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/cancers11121936","article-title":"Pituitary adenomas and invasiveness from anatomo-surgical, Radiological, and Histological Perspectives: a systematic literature review","volume":"11","author":"S Serioli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10014-017-0307-7","article-title":"New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors","volume":"35","author":"H Nishioka","year":"2018","journal-title":"Brain Tumor Pathol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"J Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"A McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref8","first-page":"878","article-title":"Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas","volume":"80","author":"S Ezzat","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1750-3639.2001.tb00405.x","article-title":"The role of hormones, growth Ffctors and their receptors in pituitary tumorigenesis","volume":"11","author":"S Ezzat","year":"2006","journal-title":"Brain Pathol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: A high throughput TMA, immunohistochemical study","volume":"97","author":"C Ram\u00edrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e1002400","DOI":"10.1371\/journal.pgen.1002400","article-title":"The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis","volume":"7","author":"T Tateno","year":"2011","journal-title":"PLoS Genet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1210\/me.2013-1412","article-title":"FGFR4 polymorphic variants modulate phenotypic features of cushing disease","volume":"28","author":"T Nakano-Tateno","year":"2014","journal-title":"Mol Endocrinol"},{"key":"ref13","first-page":"1911","article-title":"Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness","volume":"89","author":"Z R Qian","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1677\/erc.0.0070165","article-title":"Fibroblast growth factors, their receptors and signaling","volume":"7","author":"C J Powers","year":"2000","journal-title":"Endocr Relat Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/me.2004-0182","article-title":"Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule\/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia","volume":"18","author":"S Ezzat","year":"2004","journal-title":"Mol Endocrinol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/35083041","article-title":"N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling","volume":"3","author":"U Cavallaro","year":"2001","journal-title":"Nat Cell Biol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1172\/JCI14036","article-title":"Targeted expression of a human pituitary tumor\u2013derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis","volume":"109","author":"S Ezzat","year":"2002","journal-title":"J Clin Invest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.humpath.2007.10.004","article-title":"Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas","volume":"39","author":"R Gejman","year":"2008","journal-title":"Hum Pathol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.wneu.2013.09.035","article-title":"Results of immunohistochemical staining of cell-cycle regulators: The prediction of recurrence of functioning pituitary adenoma","volume":"81","author":"E H Lee","year":"2014","journal-title":"World Neurosurg"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","article-title":"Histological criteria for atypical pituitary adenomas \u2013 data from the German pituitary adenoma registry suggests modifications","volume":"3","author":"C P Miermeister","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1210\/jc.2009-0471","article-title":"Predicting recurrence of nonfunctioning pituitary adenomas","volume":"94","author":"T-W Noh","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12022-018-9563-2","article-title":"The Prognostic roles of the Ki-67 proliferation index, P53 expression, mitotic index, and radiological tumor invasion in pituitary adenomas","volume":"30","author":"R Hasanov","year":"2019","journal-title":"Endocr Pathol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S0317167100002614","article-title":"p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas","volume":"30","author":"S J Hentschel","year":"2003","journal-title":"Can J Neurol Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1227\/01.NEU.0000290906.53685.79","article-title":"A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas","volume":"61","author":"S Yamada","year":"2007","journal-title":"Neurosurgery"},{"key":"ref25","first-page":"610","article-title":"Pituitary adenomas with invasion of the cavernous sinus space","volume":"33","author":"E Knosp","year":"1993","journal-title":"Neurosurgery"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/02841859709171238","article-title":"SIPAP: A new MR classification for pituitary adenomas","volume":"38","author":"A L Edal","year":"1997","journal-title":"Acta Radiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"A Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An endocrine society clinical practice guideline","volume":"99","author":"L Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4158\/EP171887.OR","article-title":"Late-night salivery cortisol is unadulterated in patients with polycystic ovarian syndrome (PCOS), irrespective of disease phenotype, and in obese women, irrespective of the presence of PCOS","volume":"23","author":"H M Ozkaya","year":"2017","journal-title":"Endocr Pract"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"L K Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1210\/jc.2015-2107","article-title":"Accuracy of late-night salivary cortisol in evaluating postoperative remission and recurrence in Cushing\u2019s disease","volume":"100","author":"F G Amlashi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/17446651.2018.1411798","article-title":"Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes","volume":"13","author":"M J Rutkowski","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3171\/2019.11.JNS192457","article-title":"Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas","author":"M M Gerges","year":"2021","journal-title":"J Neurosurg"},{"key":"ref34","first-page":"1","volume-title":"Introduction","author":"R Y Osamura","year":"2017","edition":"4th ed."},{"key":"ref35","first-page":"14","volume-title":"Pituitary adenoma. World Heal. Organ","author":"R Y Osamura","year":"2017","edition":"4th ed."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-016-2365-9","article-title":"Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas","volume":"132","author":"X Yao","year":"2017","journal-title":"J Neurooncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1210\/jc.2013-3054","article-title":"Growth patterns of pituitary adenomas and histopathological correlates","volume":"99","author":"E Monsalves","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1210\/jc.2010-0047","article-title":"Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing\u2019s disease outcome","volume":"95","author":"L P Brito","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/dvdy.21388","article-title":"Functional evolutionary history of the mouseFgf gene family","volume":"237","author":"N Itoh","year":"2008","journal-title":"Dev Dyn"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/dvdy.21699","article-title":"Pleiotropic function of FGF-4: its role in development and stem cells","volume":"238","author":"N Kosaka","year":"2009","journal-title":"Dev Dyn"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e71641","DOI":"10.1371\/journal.pone.0071641","article-title":"Fibroblast growth factor-4 enhances proliferation of mouse embryonic stem cells via activation of c-Jun signaling","volume":"8","author":"S-H Kook","year":"2013","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.2007.03062.x","article-title":"Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit ( gsp ) mutation in human GH-secreting pituitary adenomas","volume":"68","author":"K Morita","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref43","first-page":"629","article-title":"New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope","volume":"68","author":"G Key","year":"1993","journal-title":"Lab Investig"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1523-7216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:14:03Z","timestamp":1644538443000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1523-7216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":43,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1523-7216","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]}}}